Pandemic prompts European life sciences real estate rush

* Less than 1% of European real estate in life sciences

* Less than 10% of capital for UK has been deployed -JLL

* Rents in London's 'Knowledge Quarter' exceed City rents

* Bespoke life science buildings can be hard to trade

By Carolyn Cohn

LONDON, April 20 (Reuters) - London's Francis Crick Institute was already a magnet for investors in the capital's so-called Knowledge Quarter, but the coronavirus pandemic has lifted interest in offices and laboratories dedicated to life sciences to a new level.

Investors have been drawn into European real estate dedicated to life sciences, which spans sectors such as biomedical devices and pharmaceuticals, by an ageing population and strong academic research in the region.

But the COVID-19 pandemic has fast-forwarded the script.

"Life sciences have never been more under the spotlight because of what we've all had to endure," Peter Ferrari, chief executive of real estate investor AshbyCapital, told Reuters.

In January, together with Montrose Land, AshbyCapital bought an Edwardian building near the Crick bio-medical research centre in the heart of the Knowledge Quarter life sciences hub.

The building, which should be fitted out for rental to life science tenants in 2024, was AshbyCapital's first investment in the sector and Ferrari hopes it will be a starting point for taking on "one or two more" similar projects.

Investors say there is demand in both urban centres and out-of-town science parks in Britain and other parts of Europe to accommodate an industry which tends to be recession-proof.

Real estate money is looking for new avenues as retail property and offices face the challenge of people increasingly shopping and working from home, analysts and investors say.

Commercial real estate investment volumes in Europe totalled 277 billion euros ($333 billion) in 2020, down 17% from a year earlier as a result of the coronavirus pandemic, real estate broker CBRE says.

Although less than 1% of European real estate investment is in life sciences, a recent report from the Urban Land Institute shows, strong government and venture capital investment in the sector is encouraging piggy-backing by real estate investors.

And real estate broker JLL estimates that up to 15 billion pounds ($21 billion) has been allocated to British life sciences real estate, of which less than 10% has been deployed to date.

Glenn Crocker, head of UK life sciences at JLL, said it had been approached by 20 real estate developers and investors to discuss life sciences in January, following 100 conversations in 2020, reflecting the strength of interest.

Not every area is suitable for a life sciences centre, as the infrastructure of nearby universities, major hospitals and good housing or cultural activities is also needed.

"I am a little bit sceptical about the sudden interest," Zachary Gauge, European real estate analyst at UBS, told a recent news briefing, adding that the specialist nature of life science buildings meant they could be difficult to trade.


Although Britain's so-called Golden Triangle of life sciences centres in London, Oxford and Cambridge leads the way in Europe, areas such as Bio Science Park in the Dutch city of Leiden, which is home to Johnson & Johnson JNJ.N vaccine producer Janssen, is one of several major European ones.

Private equity giant Blackstone's real estate life sciences investment in Britain, which is made through its $20 billion enterprise value portfolio company BioMed Realty, includes several science park buildings in Cambridge.

"The pandemic put the industry and its researchers in the forefront ... There is extraordinary demand for talent and space," Bill Kane, BioMed's president of East Coast and UK markets, told Reuters.

Meanwhile, British insurance and investment group Legal & General LGEN.L last year invested 200 million pounds in Oxford University's Life and Mind Building.

"Life science is derisked at the moment by the fact there is huge interest in the sector," said Eleanor Jukes, senior investment manager at L&G, adding that real estate valuations had risen due to the "huge weight of capital" looking to buy.

L&G recently sold five buildings in a Cambridge science park after a fierce bidding war for a total 97 million pounds, 59% above valuation levels.

In addition to U.S. investors and Canadian pension funds, Middle Eastern money is also showing interest, said Ghada Sousou, CEO of real estate recruitment firm Sousou Partners.

Real estate demand is outstripping supply. In Cambridge, there are lab requirements of more than 400,000 square feet, and supply of less than 100,000, Sue Foxley, research director at real estate consultancy Bidwells, said.


But the sector is not for the faint-hearted.

Life science buildings range from traditional offices and laboratories to "dry labs" - research offices with extra technology needs.

The buildings may have special requirements such as extra power supplies, arrangements for the safe disposal of hazards and higher than average ceilings.

"There's an extra cost in that," said Carl Potter, a managing director at real estate consultants Avison Young.

"That cost has to be reflected in rents."

Prime office rents in King's Cross, inside the Knowledge Quarter, are 83 pounds per square foot per annum compared with the City of London at 81 pounds and the Canary Wharf district at 51.50 pounds, according to the ULI report.

Investors and developers have to kit out buildings without necessarily knowing who their future tenants will be, and if there will be one or several.

Richard Fagg, development director at VINCI UK Developments, said this raised the question "will value be secured?", adding that "strong conviction is needed".

Developers have to be flexible so that buildings can be altered relatively easily. Industry sources say bespoke buildings can be hard to market to new tenants.

"Every commercial developer is interested in life science," said Steven Charlton, principal managing director of architects Perkins&Will, adding that the practicalities can be a deterrent.

But Gauge at UBS said there was a risk the enthusiasm for life sciences real estate could be short-lived: "I'm worried about having a kneejerk reaction to COVID." ($1 = 0.7233 pounds) ($1 = 0.8317 euros)

Cambridge Office & Labs Link

Reporting by Carolyn Cohn;
Editing by Alexander Smith

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.